Estimation of CYP2D6*10 genotypes on citalopram disposition in Chinese subjects by population pharmacokinetic assay

Journal of Clinical Pharmacy and Therapeutics

Volumn 38, Issue 6, 2013, Pages 504-511

  Chen, B ^a   Xu, Y ^a   Jiang, T ^b   Feng, R ^c   Sun, J ^a   Zhang, W ^a   Yang, W ^a   Li, J ^a   Adeniyi, O ^c   Chen, Hongzhuan ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

bioequivalence; citalopram; CYP2C19; CYP2D6; genotype; non compartment; population pharmacokinetic

Indexed keywords

CIPRIMIL; CITALOPRAM; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; CYP2C19 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CHINESE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MEASUREMENT ERROR; NORMAL HUMAN; OPEN STUDY; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; ASIAN; CONTROLLED CLINICAL TRIAL; GENETICS; MEDICINAL CHEMISTRY; NON-COMPARTMENT; POPULATION; POPULATION PHARMACOKINETIC; STATISTICAL MODEL; THERAPEUTIC EQUIVALENCE; YOUNG ADULT;

BIOEQUIVALENCE; CITALOPRAM; CYP2C19; CYP2D6; GENOTYPE; NON-COMPARTMENT; POPULATION PHARMACOKINETIC;

ADULT; ANTIDEPRESSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMISTRY, PHARMACEUTICAL; CITALOPRAM; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; GENOTYPE; HUMANS; MALE; MODELS, STATISTICAL; POLYMORPHISM, GENETIC; POPULATION; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 84886948754     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12029     Document Type: Article

References (25)

1. Baumann P, Rochat B,. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol, 1995; 10 (Suppl 1): 15-21.
2. Joffe P, Larsen FS, Pedersen V, Ring-Larsen H, Aaes-Jørgensen T, Sidhu J,. Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. Eur J Clin Pharmacol, 1998; 54: 237-242.
3. Leinonen E, Lepola U, Koponen H, Kinnunen I,. The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method. Ther Drug Monit, 1996; 18: 111-117.
4. Fredricson Overø K,. Kinetics of citalopram in man: plasma levels in patients. Prog Neuropsychopharmacol Biol Psychiatry, 1982; 6: 311-318.
5. Kobayashi K, Chiba K, Yagi T, et al,. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther, 1997; 280: 927-933.
6. Sindrup SH, Brøsen K, Hansen MG, Aaes-Jørgensen T, Overø KF, Gram LF,. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit, 1993; 15: 11-17.
7. Rochat B, Amey M, Gillet M, Meyer UA, Baumann P,. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics, 1997; 7: 1-10.
8. Olesen OV, Linnet K,. Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology, 1999; 59: 298-309.
9. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA,. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem, 1994; 269: 15419-15422.
10. Yin OQ, Wing YK, Cheung Y, Wang ZJ, Lam SL, Chiu HF, Chow MS,. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients. J Clin Psychopharmacol, 2006; 26: 367-372.
11. Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, Goldstein JA,. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. Biochem Pharmacol, 1992; 43: 2201-2208.
12. Hsieh KP, Lin YY, Cheng CL, Lai ML, Lin MS, Siest JP, Huang JD,. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos, 2001; 29: 268-273.
13. Garcia-Barcelo M, Chow LY, Chiu HF, Wing YK, Lee DT, Lam KL, Waye MM,. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin Chem, 2000; 46: 18-23.
14. Lee EJ, Jeyaseelan K,. Frequency of human CYP2D6 mutant alleles in a normal Chinese population. Br J Clin Pharmacol, 1994; 37: 605-607.
15. Cai WM, Chen B, Zhang WX,. Frequency of CYP2D6*10 and*14 alleles and their influence on the metabolic activity of CYP2D6 in a healthy Chinese population. Clin Pharmacol Ther, 2007; 81: 95-98.
16. Jiang T, Rong Z, Peng L, et al,. Simultaneous determination of citalopram and its metabolite in human plasma by LC-MS/MS applied to pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci, 2010; 878: 615-619.
17. Pentikis HS, Henderson JD, Tran NL, Ludden TM,. Bioequivalence: individual and population compartmental modeling compared to the noncompartmental approach. Pharm Res, 1996; 13: 1116-1121.
18. Kragh-Sørensen P, Overø KF, Petersen OL, Jensen K, Parnas W,. The kinetics of citalopram: single and multiple dose studies in man. Acta Pharmacol Toxicol (Copenh), 1981; 48: 53-60.
19. Bies RR, Feng Y, Lotrich FE, Kirshner MA, Roose S, Kupfer DJ, Pollock BG,. Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. J Clin Pharmacol, 2004; 44: 1352-1359.
20. Friberg LE, Isbister GK, Hackett LP, Duffull SB,. The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach. J Pharmacokinet Pharmacodyn, 2005; 32: 571-605.
21. Spigset O, Hägg S, Stegmayr B, Dahlqvist R,. Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. Eur J Clin Pharmacol, 2000; 56: 699-703.
22. Yu BN, Chen GL, He N, Ouyang DS, Chen XP, Liu ZQ, Zhou HH,. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metab Dispos, 2003; 31: 1255-1259.
23. Herrlin K, Yasui-Furukori N, Tybring G, Widén J, Gustafsson LL, Bertilsson L,. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol, 2003; 56: 415-421.
24. Fradette C, Lavigne J, Waters D, Ducharme MP,. The utility of the population approach applied to bioequivalence in patients. Ther Drug Monit, 2005; 27: 592-600.
25. Maier GA, Lockwood GF, Oppermann JA, Wei G, Bauer P, Fedler-Kelly J, Grasela T,. Characterization of the highly variable bioavailability of tiludronate in normal volunteers using population pharmacokinetic methodologies. Eur J Drug Metab Pharmacokinet, 1999; 24: 249-254.